[Dependence of the pharmacokinetics of captopril on the type of adaptation reactions in the organism].
The dependence of the pharmacokinetic profiles (PhP) of captopril in the phase of adaptation reactions in the organism has been studied within the framework of randomized, comparative, double cross research of bioeqivalency of captopril (Aspharma Co, Anzhero-Sudzhensk) and capoten (Bristol Myers Squibb Co.; official Russian producer, Akrikhin KhimFarmKombinat). It is established that the maximum bioaccessibility and high concentration of captopril in the blood plasma is determined on the background of physiologically optimum reactions of training and in the zone of quiet activation. These characteristics decrease during the reactions of general adaptation syndrome according to the type of increased activation and reactivation.
Udut
V V
VV
Khazanov
V A
VA
Gurto
R V
RV
Borodulina
E V
EV
Postnikova
Iu E
IuE
D000222:Adaptation, Physiological; D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000493:pharmacokinetics*; D000959:Antihypertensive Agents / Q000493:pharmacokinetics*; D001682:Biological Availability; D002216:Captopril / Q000493:pharmacokinetics*; D005260:Female; D005790:General Adaptation Syndrome / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002216:Captopril